Compugen (CGEN) Stock Price, News & Analysis

Company Overview

Compugen Ltd. is a clinical-stage therapeutic discovery company that specializes in computational biology and predictive discovery for immuno-oncology. Leveraging proprietary in silico platforms, Compugen identifies novel targets and biomarkers to advance its pipeline of therapeutic and diagnostic candidates. The company’s core expertise lies in the intersection of computational genomics, bioinformatics and translational medicine to accelerate the identification and validation of immune-modulating targets and companion diagnostics.

Founded in 1983 and headquartered in Holon, Israel, Compugen has evolved from a bioinformatics services provider into a fully integrated discovery and development organization. Over the years, the company has forged collaborations with global pharmaceutical and biotech partners, including major alliances to advance its lead product candidates. Compugen’s pipeline encompasses multiple checkpoint pathway targets and translational diagnostic programs, with several late-stage clinical assets aimed at addressing solid tumors and hematological malignancies.

Compugen serves a global customer base and maintains research facilities in Israel and the United States, as well as strategic offices in New York. The company’s commercial efforts are complemented by its proprietary platforms—Predictive Target Discovery and Predictive Biomarker Discovery—that support both in-house development and collaborative projects. Through these platforms, Compugen has generated a robust portfolio of immuno-oncology discoveries and companion diagnostic candidates that aim to enhance the precision and efficacy of cancer therapies.

The company is governed by an experienced management team and board of directors, led by its President and Chief Executive Officer, who brings more than two decades of biopharmaceutical leadership. Under this leadership, Compugen continues to expand its discovery engine, advance its clinical programs and pursue strategic partnerships to bring novel immuno-oncology solutions to patients worldwide.

Key Stats

• Today's Range: $1.66 to $1.73
• 50-Day Range: $1.25 to $1.83
• 52-Week Range: $1.13 to $2.66
• Volume: 113,511 shs
• Average Volume: 363,989 shs
• Market Capitalization: $149.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Compugen Stock Analysis - MarketRank™

Compugen scored higher than 28% of companies evaluated by MarketBeat, and ranked 762nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Compugen has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compugen is -10.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compugen is -10.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Compugen has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.81% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Compugen has recently decreased by 0.68%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compugen does not currently pay a dividend.

Dividend Growth

Compugen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.81% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Compugen has recently decreased by 0.68%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for CGEN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Compugen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of Compugen is held by insiders.

Percentage Held by Institutions

Only 12.22% of the stock of Compugen is held by institutions.

CGEN Stock Analysis - Frequently Asked Questions

How have CGEN shares performed this year?

Compugen's stock was trading at $1.53 at the beginning of the year. Since then, CGEN shares have increased by 9.2% and is now trading at $1.67.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Monday, May, 19th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.02. The biotechnology company had revenue of $2.28 million for the quarter, compared to analysts' expectations of $3.70 million. Compugen had a negative net margin of 51.27% and a negative trailing twelve-month return on equity of 24.51%.
Read the conference call transcript.

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and

Company Calendar

• Last Earnings: 5/19/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGEN
• CIK: 1119774
• Web: www.cgen.com
• Phone: (723) 765-8585
• Fax: 972-3765-8555
• Employees: 70
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Compugen: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +139.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.23 million
• Net Margins: -51.27%
• Pretax Margin: -34.78%
• Return on Equity: -24.51%
• Return on Assets: -12.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.09
• Quick Ratio: 5.09

Sales & Book Value

• Annual Sales: $27.86 million
• Price / Sales: 5.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 2.69

Miscellaneous

• Outstanding Shares: 89,240,000
• Free Float: 80,759,000
• Market Cap: $149.03 million
• Optionable: Optionable
• Beta: 2.57